Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
View Patent ↗An objective of the present invention is to provide novel therapeutic agents for cancer, which have an excellent antitumor effect in cancer patients by enhancing their immune function. The present inventors discovered that the administration of at IL-6 inhibitor and/or gemcitabine or a salt thereof to tumor-bearing organisms yields an excellent antitumor T cell response-enhancing effect, and completed the present invention. In addition, the present inventors discovered that the T cell response-enhancing effect produces an excellent antitumor effect.
1. A method for enhancing an antitumor T cell response and suppressing tumor growth in a tumor-bearing organism in need thereof, which comprises administering an anti-interleukin 6 (IL-6) receptor antibody and gemcitabine or a salt thereof to a tumor-bearing organism, wherein antitumor T cell response is enhanced and tumor growth is suppressed in the tumor-bearing organism in need thereof, and wherein the tumor-bearing organism has a cancer selected from the group consisting of stomach cancer, prostate cancer, head and neck cancer, breast cancer, lung cancer, colon cancer, and ovarian cancer, wherein the anti-IL-6 receptor antibody is a MR16-1 antibody or a PM-1 antibody.
2. The method of claim 1 , wherein the MR16-1 antibody or the PM-1 antibody is a chimeric antibody, a humanized antibody, or a human antibody.